pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

GLAXOSMITHKLINE

USupdated 3mo ago
Website ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatmentsrecruitingn=123
  • phase2A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumoursnot yet recruitingn=155
  • phase2A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Ageactive not recruitingn=465
  • phase3A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)recruitingn=380
  • phase2A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumorsrecruitingn=47
  • phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=494
  • phase3A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)recruitingn=624
  • phase3A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)recruitingn=370
🐶 Hiring Signal
No open roles indexed yet — view GLAXOSMITHKLINE jobs →

News

  • Ramaswamy’s biotech baggage haunted his political run
    A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
    biopharma_dive · 10d ago
  • STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
    A U.S. judge rejected a bid to block ‌Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs
    stat · 23d ago
  • Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 28d ago
  • Chai Discovery signs GSK deal to make biologics with AI
    At the start of 2026, Joshua Meier pitched his startup's collaboration with Eli Lilly as just the beginning. Meier's vision of a "year of deployment" has been more than an aspiration, as ...
    endpoints · 1mo ago
  • No more Nordisk as Novo goes it alone amid rebranding push
    As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebrand of its business, logo and name.
    fiercebiotech · 2mo ago
  • TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan
    TwinStrand Biosciences wins patent case: The DNA sequencing company, which spun out of the University of Washington, announced on Monday that it won a patent infringement lawsuit against a Californ…
    endpoints · 2mo ago
  • FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout
    GSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and th…
    endpoints · 4mo ago
  • STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
    The number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026
    stat · 4mo ago
  • Beyond Boston: Unlikely cities stake biotech claims
    As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
    biopharma_dive · 4mo ago
  • Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist
    → Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics, which is partnering with GSK on Alzheimer’s treatments. Balice-Gordon will slide over to ...
    endpoints · 4mo ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?